There are two types of treatment for macular enema: focal laser therapy that slows the leakage of fluid, and medications that can be injected into the eye that slow the growth of new blood vessels and reduce the leakage of fluid into the macula. There are several treatments for glaucoma. For abnormal blood vessel growth neovascularization, the laser treatments are delivered over the peripheral retina. Prognosis depends upon the extent of the retinopathy, the cause, and promptness of treatment. This test measures pressure inside the eye. no dataCorticosteroids. People with diabetes do have a higher risk of blindness than people without diabetes. People with diabetes type 1 and type 2 ares 25 times more likely to experience vision loss than people without diabetes. Leitgeb A, et al. What Happens if Diabetic Retinopathy Is Not Treated? Ongoing inflammation and vascular remodelling may occur over periods of time where the patient is not fully aware of the extent of the disease. Vitrectomy.
Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease. Scope The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor. – What are the competitive advantages of the existing novel drugs? http://www.aprasw.org/advisingeyesurgeon/2016/08/29/outlines-for-locating-criteria-of-keratoconus/With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies. – Which classes of novel drugs are most prominent within the pipeline? – Is there strong potential for the pipeline to address unmet needs within the T2DM market? Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%. – How do failure rates vary by product stage of development, molecule type, and mechanism of action? – How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development? Over the 2015-2022 forecast period, the South-East Asia T2DM therapeutics market is expected to increase in value at a CAGR of 7.1%, from $1.7 billion to over $2.7 billion. – Which markets make the most significant contribution to the current market size?
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/type-2-diabetes-mellitus-therapeutics-in-south-east-asia-markets-to-2022—increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth-300328336.html